Lifeline Sci Share Discussion Threads

[cragside] 16/2/2016 16:37

I recently came across this company using a homegrown Momentum filter. Very illiquid, and US based which is not ideal. But hey the company is profitable, well established, great chart, and in a niche market so could be a winner. A little surprised that the positive trading update on 19/1/16 did not receive better reaction.

[interceptor2] 16/2/2016 14:49

Pleased to see these slowly creep up, even more impressive against the nervous market backdrop. There has been constant small scale buying here in the last few weeks.

Panmure Gordon still have LSIC under review, shame that can't be bothered to give some market estimates.

[pejaten] 10/2/2016 11:09

maybe the strategic review conclusions are imminent.....

[cfro] 10/2/2016 10:48

Slowly gaining the recognition it deserves given how well trading is going?

[cfro] 22/1/2016 14:27

Well we have had two trading updates in the short space of a month, so perhaps management are trying to keep investors more informed on a more regular basis.

[2vdm] 22/1/2016 14:21

I think "off the radar" sums it up. Happy to see the trading update, but for some reason this share has never taken off. I bought 2011 at 221p after a RHPS tip. It is frustrating that the BOD rarely give updates. One day I hope it rockets, but for me it's a "leave in the bottom drawer share" and dust it off annually when results come out.

[cfro] 19/1/2016 18:05

Very high volume day today. Must be a couple of insti's cross-trading.

[cfro] 19/1/2016 14:24

Also back in today.

Only cloud which could hang over this is the review.

[interceptor2] 19/1/2016 14:00

Pleased to see you here Saucepan :o)

I have bought a few more today, for some reason I didn't buy my normal portfolio weighting here in December. Error corrected now.

[saucepan] 19/1/2016 13:48

Thanks for the heads up, IC2. I have just taken an initial position with a view to long term hold if possible.

[boonkoh] 19/1/2016 11:33

For some reason still so lowly valued. Granted both Brazil and China are probably scaring all the investors, but this is a defensive sector (healthcare) and transplants are not discretionary spending items.

[interceptor2] 19/1/2016 09:22

Still nicely off the radar.

Great trading update and good to have figures in the update to work out the likely results.

Even when I work out the PAT at tax neutral (haven't worked out any tax credit yet) EPS is 27.7c. Seems good value to me given the cash position and future positive outlook.

[eezymunny] 19/1/2016 08:19

Rather rocking H2 numbers! Had a few for the EEZY3 portfolio FWIW.

[my retirement fund] 30/12/2015 13:22

ZZZZzzzz.....

[sailing john] 18/12/2015 14:37

Bought back in today after being out since September.

Very positive TS - now holding more than earlier this year

Quite surprised that stock available in decent volume although had to place orders above the offer, filled at 195/188

A potential multi year hold - again!

Nice off radar stock with a very quiet thread

GL - SJ

[my retirement fund] 18/12/2015 12:13

I have followed these for years and held them on and off. I was hoping for some guidance on the strategic review and still zip! So this has put me off.

[cfro] 18/12/2015 11:42

I too bought in here today. Orders seem to be picking up in the US, China and Brazil.

[wjccghcc] 18/12/2015 11:14

Hi rivaldo, I've had a holding for a while. Brokers forecasts are not particularly reliable or up to date and often it's not clear if they're in cents or pence. Last year's PBT was $2.3mm with earnings of 11c though that EPS included a deferred tax credit exceptional item which is probably why the EPS forecast was lower.

The thing I like about them is their dominant market share in a growing market and the fact that they spend a lot on the regulatory process which should reduce now China is approved and one the Liver Lifeport is approved.

[interceptor2] 18/12/2015 10:58

I did buy in here this morning after the materially ahead adjusted PBT trading update, have been researching the company this morning and it does seem like business is accelerating particularly in China and Brazil.

Hi Rivaldo, I was struggling to find any recent broker estimates, noticed that Panmure are currently under review. I can only go with the market estimate provided in today's RNS, they said that market estimates were for adjusted PBT of $3.40m which would mean EPS 17.43c or 11.67p at current exchange rates. I don't think there will be much tax this year, so haven't adjusted for tax.

To use the phrase materially ahead in itself certainly shows confidence in future prospects.

[rivaldo] 18/12/2015 10:18

Just looking in here. Good statement today, but can anyone please explain why forecasts have dropped drastically recently for this year to 6.46p EPS (from 10.81p EPS):

[zipstuck] 18/12/2015 08:07

The last results gave the clue to todays trading statement. Nice to get a company that does what it says on the tin.

[rambutan2] 22/9/2015 15:33

Kept an eye on them for years, but met management at end of April. Was really impressed and it was clear that it was time to buy, however, price was drifting up and I hoped it would halt, or a seller appear. I should've known better, it being such an illiquid share and so ended up only picking up a few as I watched it rise and rise. Ho humm...

[wjccghcc] 22/9/2015 10:09

Also following. Have a reasonable sized holding but never really much to add to the discussion.

[2vdm] 22/9/2015 09:26

Hi Sailor J. Looks like rambutan2 has joined this highly active thread. The excitement is killing me, but at least the share price is edging up!

[rambutan2] 22/9/2015 02:47

To accompany today's good interims ( )...

21 September 2015

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Strategic review

Lifeline set to explore strategic and financial alternatives aimed to increase shareholder value

Lifeline Scientific (AIM: LSIC), the transplantation technology company, announces that its Board of Directors has determined to explore a full range of strategic and financial alternatives to enhance shareholder value, and the Company has retained Piper Jaffray to assist in the process.

The Board believes that the Company is at an inflection point in its growth, and that opportunities represented by its existing business combined with China's Food and Drug Administration (CFDA) approvals of LifePort Kidney Transporter and related single-use consumables and solutions, recent progress in Brazil and the prospects of LifePort Liver Transporter, are not reflected in the Company's current market value. Consequently the Board plans to explore a range of options, which could include (though will not be limited to), a strategic merger, strategic acquisitions, a potential sale of the Company, and a potential listing of the Company's shares on the NASDAQ market.

Commenting David Kravitz, CEO of Lifeline Scientific, said:

"Our board is focused on maximising shareholder value in this time of significant opportunity within the global transplant market. Accordingly, we will thoroughly explore the full range of strategic and financial alternatives available to capitalise on our market-leading platform of LifePort based organ recovery and preservation products, and our premium global brand. All options will be thoroughly reviewed and we will take the time we require to evaluate our opportunities, and achieve the best results for our shareholders, business partners and associates."

The Board is at the beginning stage of its strategic and financial review, and no assurance can be given as to its outcome or timing. The Company does not presently intend to make any further public comment regarding the review unless and until the board approves the outcome of the review.